Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.

Similarly, increased PD-1 and CD137 levels were detected, but this did not reach statistical significance ( figure 3C and online supplemental figure S3B ). cDC1s treated with higher doses (1 μM) of both XCR1-targeted and control constructs induced similar CD8 + T cell proliferation, and activation ( figure 3B–D ).

also in 111,027 other papers